newsfilter
← Latest News
GlobeNewswire·

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in